Business
Trevi Therapeutics to Participate in Upcoming June Conferences
NEW HAVEN, Conn., May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"NEW HAVEN, Conn., May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in June.\n\n \n \n \n \n \n \n\n \nAmerican Cough ConferenceJune 6 – 7, 2025, Dulles, VirginiaOral Presentation: June 6, 4:05 p.m. ETPresentation: Baseline demographics and characteristics from the RIVER trial evaluating nalbuphine extended-release tablets in patients with refractory chronic coughTrevi Representatives: Jennifer Good, President and CEO, James Cassella, Ph.D., CDO, Danine Summers, VP of Medical Affairs and Abbey Nakano, Pharm.D., AD of Medical AffairsRegister here\nCPDD 87th Annual Scientific MeetingJune 14 – 18, 2025, New Orleans, LouisianaPoster Presentation: June 18, 2:00 p.m. CTPoster: Assessment of Human Abuse Potential of Nalbuphine in Non-Dependent Recreational Drug UsersPoster Session: 4Trevi Representative: Thomas Sciascia, M.D., Co-Founder and CSORegister here\nBIO International ConventionJune 16 – 19, 2025, Boston, MassachusettsCorporate Presentation: June 17, 12:15 p.m. ETTrevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCORegister here\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials with IPF chronic cough patients and RCC patients. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. \nChronic cough is a highly prevalent condition in IPF patients, impacting up to 85% of the IPF population. There are ~150,000 U.S. IPF patie...